Publicaciones en las que colabora con Juan Luis García Hernández (10)

2016

  1. Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes

    PLoS ONE, Vol. 11, Núm. 10

2012

  1. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

    Pharmacogenetics and Genomics, Vol. 22, Núm. 5, pp. 381-388

2010

  1. Immunomodulatory effect of 5-azacytidine (5-azaC): Potential role in the transplantation setting

    Blood, Vol. 115, Núm. 1, pp. 107-121

2009

  1. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome

    Leukemia, Vol. 23, Núm. 4, pp. 664-672

  2. Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

    Leukemia Research, Vol. 33, Núm. 1, pp. 170-173

  3. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

2005

  1. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes [7]

    Leukemia

2000

  1. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia

    Annals of Oncology, Vol. 11, Núm. 4, pp. 441-444

  2. Cytogenetic abnormalities are associated with immunophenotypic changes in refractory anemias

    Blood, Vol. 96, Núm. 11 PART I

1998

  1. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders

    Haematologica, Vol. 83, Núm. 1, pp. 3-7